Leadership Team

Kaitin9aa headshot 2015.png

Kenneth I Kaitin PhD, Director

Kenneth Kaitin is a Professor at Tufts University School of Medicine and Senior Fellow at Tufts Center for the Study of Drug Development. He is also Advisory Professor at Shanghai Medical College at Fudan University and serves on the faculty of the European Center for Pharmaceutical Medicine at the University of Basel. Dr. Kaitin is internationally recognized for contributions to the fields of drug development policy and science. He consults, speaks, and writes on global trends in pharmaceutical development, and he has provided public testimony before the U.S. Congress. A former President of the Drug Information Association, Dr. Kaitin recently served as Editor-in-Chief of Expert Review of Clinical Pharmacology, and as a consultant to the U.S. Department of Defense on bioterror countermeasures. In 2011, he received the Dr. Louis M. Sherwood Award, granted by the Academy of Pharmaceutical Physicians and Investigators; in 2020 he was named Global Fellow in Medicines Development by the International Federation of Pharmaceutical Physicians, and in 2021 he received the Distinguished Achievement Award from the Sino-American Pharmaceutical Professionals Association (SAPA). Dr. Kaitin is a director on the boards of Curis, Inc. (NASDAQ: CRIS), Bio-Tree Systems, Inc., and QCDx. He earned his BS from Cornell University and MS and PhD in pharmacology from the University of Rochester

QCDx Profile Pic_edited.jpg

Fahmy A Mamuya PhD, MBA, Lead Scientist

Fahmy has 10+ years of professional experience in academia, clinical, and industrial settings. In addition to his expertise in oncology medical communications, Dr. Mamuya has a strong background in high-end research imaging gained from his biomedical research studies and his roles as a research imaging specialist within the microscopy industry. He received a Ph.D. in Cells, Organs, and System Physiology from the University of Delaware. He studied epithelial cell behavior after injury/surgery and showed excellent potential for secondary cataract therapeutics that are currently under development. Dr. Mamuya continued his academic research career as a Post-Doctoral Fellow at Massachusetts General Hospital and Harvard Medical School and published his work on integrin receptors' critical roles in kidney development and function. He holds an MBA from the University of Delaware and is Adjunct Professor at Bay Path University Master's program in Applied Laboratory Science & Operations.


Harry H Penner JD LLM, Co-Founder & Chairman

Harry has 30+ years of executive experience in the pharmaceutical and biotechnology sectors. He is currently on the Board of Directors of Prevention Pharmaceuticals, Affinimark Technologies, Neurovail, Aria Neurosciences, and Carogen. He has been a director of Celldex since the merger between Celldex and AVANT Immunotherapeutics in March 2008 and had been a director of AVANT since 1997. In 2001, he founded Nascent BioScience, a firm engaged in the creation and development of new biotechnology companies, where he is currently Chairman and Chief Executive Officer. From 1993 to 2001, he was President, Chief Executive Officer, and Vice Chairman of Neurogen Corporation. From 1985 to 1993, he was an Executive Vice President of Novo Nordisk A/S, serving from 1988 to 1993 as Executive Vice President for North America and President, Novo Nordisk of North America. From 1985 to 1988 he was the company's Executive Vice President and General Counsel in Denmark. He has served as BioScience Advisor to the Governor and the State of Connecticut, Co-Chair of Connecticut United for Research Excellence, Chair of the Connecticut Board of Governors of Higher Education, and Chair of the Connecticut Technology Council. Mr. Penner received a B.A. from the University of Virginia, a J.D. from Fordham University, and an L.L.M. in International Law from New York University


S. Michael Sharp, PhD,  Senior Advisor Quality & Regulatory 

Michael is a Senior Regulatory Affairs and Clinical Research Executive, with more than 40 years of experience in the development and approval of medical devices. He is a Fellow of the Regulatory Affairs Professional Society and the American Society of Laser Medicine and Surgery. He has been responsible for the development and prosecution of 510(k)s, PMAs, and NDAs as well as numerous IND, IDE, and CE Mark Technical Dossier submissions for multiple Medical Devices. Also for the conception, planning, and conduct of clinical trials of both medical devices and drugs, including multi-national, multi-center trials, Phase 1 first in man oncology studies, and pivotal PMA trials. He has held Senior Executive Regulatory positions among others at Kinexum, MOJ Clinical and Medical Case Reports, Eqalix, Inc., Becker & Associates/NSF, AngioDynamics, Inc., ConforMIS, Inc., Ikonisys, Inc., Winship Cancer Institute, Emory University School of Medicine, AAI International, Div. of AAI Pharma, Synthes, USA, Intelligent Surgical Lasers, VISX, Inc, How-medica, Div. of Pfizer. Dr. Sharp received a BA from Chapman University and a PhD from California Coast University.


Liming Shao PhD, Advisor to the Board

Liming is a Professor of Medicinal Chemistry at School of Pharmacy, Fudan University, Shanghai, and Director of the Shanghai Center for Drug Discovery & Development. Prior to joining Fudan University, Liming was a senior director at Sepracor Inc./Sunovion Pharmaceuticals Inc. in drug discovery research.  For over 30 years, as a medicinal chemist, Liming participated in or led programs that cover a broad range of drug discovery research and development and which have resulted in 20 advanced leads for preclinical development for the treatment of pain, depression, ADHA, schizophrenia, Parkinson’s disease and the acceptance by the FDA of 4 IND applications and 1 NDA. Liming’s academic training was at the Tokyo University where he received his Ph.D. in Organic Chemistry followed by a postdoctoral fellowship at Harvard University.

Tafas Headshot very small.jpg

Triantafyllos (Fyl) Tafas PhD, Founder, CEO & Director

Fyl is a Life Sciences entrepreneur and developer of precision diagnostics aiming to transform human health. He founded QCDx in 2017 to develop and commercialize a next-generation rare cell detection technology, by leading a multi-disciplinary team, working at the intersection of genomics, optics, microfluidics, and big data. He co-founded Ikonisys Inc. in 2000 and served as the CSO, CTO and then President a robotic microscopy platform and diagnostic products used by major clinical customers in the US and Europe to deliver more than 300,000 cancer diagnostic tests. Prior to that, he developed a new prenatal Down screening biomarker which was licensed to Chromavision (Clarient Inc. /Neogenomics) and introduced the first Prenatal Chromosomal Abnormalities Screening Program for Greece. He co-authored more than seventy publications and is the co-inventor to 38 US patents and multiple patents pending. He was awarded the prestigious Jefferson Medal Award by the New Jersey Intellectual Property Law Association and the Distinguished Services Award from the University of Athens, Greece. He is holding a B.S. in biology and Ph.D. in ecology and populations biology from the University of Athens, 


Andreas Typaldos, Director

Mr. Typaldos is a veteran and pioneer software and technology entrepreneur, as well as founder and/or owner of businesses in the hospitality and other commercial areas. He has been founder and founding or early investor of a number of software and technology companies in the US and Europe through a Typaldos Family Office. He has deep and broad management and enterprise development experience, with expertise and international and financial contacts, over a wide range of industries. He is CEO of Xandros Inc. He co-founded Cogia GMBH (Frankfurt, DE). He is the major shareholder of CoinAnalyst. He is Executive Chairman of Bridgeways Inc and Chairman of Arkados Group Inc. He is the founder, CEO, and venture partner of the Kerna Group, and Chairman or CEO of a number of Group companies. He is Chairman and CEO of Scalix Corporation. He is holding a BS in Mathematical Methods for Engineering and Operations from Columbia University and a Masters in Computer Science from Pratt Institute.